HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aflibercept improves outcome in eyes with poor vision from neovascular age-related macular degeneration.

AuthorsOren Tomkins-Netzer, Sophie Seguin-Greenstein, Malgorzata Woronkowicz, Sue Lightman
JournalActa ophthalmologica (Acta Ophthalmol) Vol. 95 Issue 4 Pg. e342-e344 (06 2017) ISSN: 1755-3768 [Electronic] England
PMID27654888 (Publication Type: Letter)
Chemical References
  • Recombinant Fusion Proteins
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Aged, 80 and over
  • Female
  • Humans
  • Intravitreal Injections
  • Male
  • Receptors, Vascular Endothelial Growth Factor (administration & dosage, antagonists & inhibitors)
  • Recombinant Fusion Proteins (administration & dosage)
  • Treatment Outcome
  • Visual Acuity
  • Wet Macular Degeneration (diagnosis, drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: